Reduced Toxicity Conditioning Regimen: Jasper's lead asset, briquilimab, offers a novel approach to conditioning for stem cell transplants and gene therapies, aiming to deplete hematopoietic stem cells with significantly less toxicity compared to traditional chemotherapy and radiation.

Expanded Patient Eligibility: The less toxic conditioning regimen developed by Jasper could broaden the pool of eligible patients for potentially curative stem cell transplants and gene therapies, including those who are currently too frail or elderly to undergo standard procedures.

Broad Therapeutic Pipeline Potential: The company's CD117-targeting platform has wide applicability across numerous indications, including hematologic malignancies (AML, MDS), genetic disorders (SCID, Fanconi Anemia), autoimmune diseases, and as a preparatory regimen for various gene therapies.